• Profile
Close

Trends in prostate cancer incidence rates and prevalence of prostate-specific antigen screening by socioeconomic status and regions in the US, 2004-2013

The Journal of Urology Oct 04, 2017

Houston KA, et al. - This trial gauged the existence of similar decreases in the prevalence of prostate-specific antigen (PSA) screening and prostate cancer incidence rates, following the US Preventive Service Task Force (USPSTF) recommendations against routine PSA, across socioeconomic groups and US census regions. The early-stage disease in men 50 years and older, reported a decrease in the prostate cancer incidence. On the other hand, the rates for distant-stage disease illustrated a minor increase in men 50-74 years following USPSTF recommendations against routine PSA screening. In order to affirm the yielded results and to monitor the upshot of late-stage disease increase on prostate cancer mortality rates, additional analyses were requisited.

Methods

  • The incidence rates and PSA screening prevalence were contemplated by age, race/ethnicity, disease stage, US region, and area-level socioeconomic status.
  • An inspection was pursued of the annual percent changes for variations in the rates over time.
  • This was followed by an estimation of the predicted marginal probability and 95% confidence intervals (CI) to determine the changes in PSA screening.

Results

  • Decreased incidence rates were reported for men aged ≥50 years, in all race/ethnic, regional, and SES groups.
  • The overall incidence rates for localized cancers decreased notably by 7.5% (95% CI; -10.5, -4.4) per year in age 50-74 years and by 11.1% (95% CI; -14.1, -8.1) per year in aged ≥75 years, from 2007-2013.
  • The incidence for distant-stage cancer, on the other hand, displayed a marked rise by 1.4% (95% CI; 0.3, 2.5) per year from 2008-2013 in age 50-74 years.
  • However, it stabilized from 2011-2013 in age ≥75 years (5.1% per year, 95% CI; -3.4, 14.4).
  • Increased distant-stage disease rates were unveiled with increasing poverty-level in age 50-74, but not in age ≥75 years.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay